Citations

Showing 10 of 108094 citations.

A Need for Digitally Inclusive Health Care Service in the United States: Recommendations for Clinicians and Health Care Systems
Sharma, Pravesh , Patten, Christi A. , Sharma, Pravesh

Mayo Clinic

The Permanente Journal | July 20, 2022 | Volume: 26 | Issue: 3 | Pages: 149-153

10.7812/tpp/21.156 | PMID 35939597 Get It

Clinical Faceoff: Latarjet Versus Free Bone Block Procedures for Anterior Shoulder Instability
Menendez, Mariano E. , Barth, Johannes , Tokish, John M. , Menendez, Mariano E.

Mayo Clinic

Clinical Orthopaedics & Related Research | July 20, 2022 | Volume: 480 | Issue: 9 | Pages: 1657-1661

10.1097/corr.0000000000002324 | PMID 35857346 Get It

Subclinical High-Resolution Chest CT Scan Features In Psoriasis
Al‐Qarqaz, Firas , Obeidat, Omar , Bataineh, Zineb, Ramadan, Anoud, Zubaidi, Ghid Al, Alwani, Mustafa , Abualnaaj, Dina, Za’nouneh, Fares J. Abu, Balas, Hassan Al, Zoubi, Khalid Al, Almomani, Yassmen, Samrah, Randa S. , Kubbara, Aahd , Samrah, Shaher M. , Khassawneh, Basheer Y.

Mayo Clinic

No container title available | July 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1406730/v2 Get It

Abstract Background: Although psoriasis is considered a systemic disease, no clear association has been established between psoriasis and lung diseases. This study aims to detect and describe subclinical pulmonary involvement in psoriasis patients with various degrees of cutaneous manifestations.Methods: Adult psoriasis patients with no known active pulmonary disease or respiratory symptoms were screened for subclinical pulmonary manifestations and possible parenchymal changes using high-resolution computed tomography (HRCT) scan of the chest. Patients were classified according to the severity of skin manifestations. The clinical characteristics and radiographic findings of these patients were evaluated.Results: Fifty-nine patients with psoriasis were included, among which 47 (79.7%) had abnormal HRCT scan features. Micronodules were the most common detected lung lesions (66.1%), followed by nonspecific interstitial changes (32.2%), including pleuro-parenchymal band/atelectasis, scarring, and focal ground-glass opacities. Other HRCT findings included emphysematous changes and calcified granulomas. Abnormal HRCT findings correlated with older age and duration of psoriasis but not with the severity of skin manifestations.Conclusions: Micronodules and minor focal nonspecific interstitial changes were the most detected lung alterations in patients with psoriasis. These findings of the pilot study highlight a possible pulmonary involvement in patients with psoriasis. Larger multicenter studies are needed to clarify these findings further.
Earlier Intervention in Asymptomatic Chronic Aortic Regurgitation—Novel Indicators of Myocardial Overload
Anand, Vidhu , Nishimura, Rick A., Rigolin, Vera H.

Mayo Clinic

JAMA Cardiology | July 20, 2022 | Volume: 7 | Issue: 9 | Pages: 883

10.1001/jamacardio.2022.2115 | PMID 35857301 Get It

Long‐term experience with intraoperative electron radiation therapy boost in extremity sarcoma
Laughlin, Brady S. , Golafshar, Michael A. , Lin, Keldon K. , Goulding, Krista , Roesler, Kimberly, Vern-Gross, T.Z., Seetharam, ­Mahesh , Ashman, Jonathan B. , Lin, Keldon, Vern-Gross, Tamara, Zaniletti, Isabella, Golafshar, Michael , Laughlin, Brady S , Zaniletti, Isabella

Mayo Clinic

Journal of Surgical Oncology | July 20, 2022 | Volume: 126 | Issue: 7 | Pages: 1279-1287

10.1002/jso.27024 | PMID 35856506 Get It

AbstractBackgroundIn patients with extremity soft tissue sarcoma (eSTS), we describe outcomes of preoperative external beam radiation therapy (EBRT), limb‐sparing surgery (LSS), and intraoperative electron radiation therapy (IOERT).MethodsOne hundred and eighteen patients with eSTS treated between October 17, 2002 and July 28, 2021 were identified. EBRT was delivered preoperatively followed by LSS and IOERT.ResultsThe median follow‐up was 24.9 months. The presentation was primary in 102 (94%) patients and recurrent in 6 (6%) patients. Tumor location was lower extremity in 82 (76%) patients and upper extremity in 26 (24%) patients. Stage distribution was as follows: 3 (3%) IA, 24 (22%) IB, 31 (29%) II, 24 (22%) IIIA, and 25 (23%) IIIB. Final surgical margins were negative in 96 (89%) patients. The 5‐year local control, failure‐free survival, and overall survival were 94%, 75%, and 64%, respectively. Univariate analysis identified age >50, lower extremity, and higher grade as significant negative prognostic factors for overall survival. Grade 3 fracture or osteoradionecrosis requiring surgical fixation, neuropathy, and lymphedema occurred in 7 (6%), 1 (1%), and 0 patients, respectively.ConclusionsThis study represents one of the largest series using preoperative EBRT, LSS, and IOERT for eSTS, with high local control and a low rate of late severe toxicity.
Proteomic Biomarkers of the Apnea Hypopnea Index and Obstructive Sleep Apnea: Insights into the Pathophysiology of Presence, Severity, and Treatment Response
Cederberg, Katie L.J. , Hanif, Umaer , Sempere, Vicente Peris, Leary, Eileen , Schneider, Logan , Lin, Ling , Zhang, Jing , Blackman, Adam , Schweitzer, Paula K. , Kotagal, Suresh , Bogan, Richard , Kushida, Clete A. , Ju, Yo‐El S. , Turnbull, Chris D. , Mignot, Emmanuel , Group, The STAGES Cohort Investigator, Leary, Eileen B , Bogan, Richard , Turnbull, Chris D , Kushida, Clete A , Hedou, Julien Jacques , Morse, Anne Marie , Petousi, Nayia , Group, The STAGES Cohort Investigator

Mayo Clinic

International Journal of Molecular Sciences | July 20, 2022 | Volume: 23 | Issue: 14 | Pages: 7983

10.3390/ijms23147983 | PMID 35887329 Get It

Obstructive sleep apnea (OSA), a disease associated with excessive sleepiness and increased cardiovascular risk, affects an estimated 1 billion people worldwide. The present study examined proteomic biomarkers indicative of presence, severity, and treatment response in OSA. Participants (n = 1391) of the Stanford Technology Analytics and Genomics in Sleep study had blood collected and completed an overnight polysomnography for scoring the apnea–hypopnea index (AHI). A highly multiplexed aptamer-based array (SomaScan) was used to quantify 5000 proteins in all plasma samples. Two separate intervention-based cohorts with sleep apnea (n = 41) provided samples pre- and post-continuous/positive airway pressure (CPAP/PAP). Multivariate analyses identified 84 proteins (47 positively, 37 negatively) associated with AHI after correction for multiple testing. Of the top 15 features from a machine learning classifier for AHI ≥ 15 vs. AHI < 15 (Area Under the Curve (AUC) = 0.74), 8 were significant markers of both AHI and OSA from multivariate analyses. Exploration of pre- and post-intervention analysis identified 5 of the 84 proteins to be significantly decreased following CPAP/PAP treatment, with pathways involving endothelial function, blood coagulation, and inflammatory response. The present study identified PAI-1, tPA, and sE-Selectin as key biomarkers and suggests that endothelial dysfunction and increased coagulopathy are important consequences of OSA, which may explain the association with cardiovascular disease and stroke.
Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor
Sahoo, Dipak Kumar , Borcherding, Dana C. , Chandra, Lawrance C., Jergens, Albert E. , Atherly, Todd, Bourgois‐Mochel, Agnes, Ellinwood, N. Matthew , Snella, Elizabeth , Martin, Martin, Mochel, Jonathan P. , Sahoo, Dipak K , Mochel, Jonathan P , Severin, Andrew Josef , Allenspach, Karin

Mayo Clinic

Cancers | July 20, 2022 | Volume: 14 | Issue: 14 | Pages: 3525

10.3390/cancers14143525 | PMID 35884586 Get It

Lipopolysaccharide (LPS) is associated with chronic intestinal inflammation and promotes intestinal cancer progression in the gut. While the interplay between LPS and intestinal immune cells has been well-characterized, little is known about LPS and the intestinal epithelium interactions. In this study, we explored the differential effects of LPS on proliferation and the transcriptome in 3D enteroids/colonoids obtained from dogs with naturally occurring gastrointestinal (GI) diseases including inflammatory bowel disease (IBD) and intestinal mast cell tumor. The study objective was to analyze the LPS-induced modulation of signaling pathways involving the intestinal epithelia and contributing to colorectal cancer development in the context of an inflammatory (IBD) or a tumor microenvironment. While LPS incubation resulted in a pro-cancer gene expression pattern and stimulated proliferation of IBD enteroids and colonoids, downregulation of several cancer-associated genes such as Gpatch4, SLC7A1, ATP13A2, and TEX45 was also observed in tumor enteroids. Genes participating in porphyrin metabolism (CP), nucleocytoplasmic transport (EEF1A1), arachidonic acid, and glutathione metabolism (GPX1) exhibited a similar pattern of altered expression between IBD enteroids and IBD colonoids following LPS stimulation. In contrast, genes involved in anion transport, transcription and translation, apoptotic processes, and regulation of adaptive immune responses showed the opposite expression patterns between IBD enteroids and colonoids following LPS treatment. In brief, the crosstalk between LPS/TLR4 signal transduction pathway and several metabolic pathways such as primary bile acid biosynthesis and secretion, peroxisome, renin–angiotensin system, glutathione metabolism, and arachidonic acid pathways may be important in driving chronic intestinal inflammation and intestinal carcinogenesis.
PPV of the Molecular Breast Imaging Lexicon
Hunt, Katie N. , Conners, Amy Lynn , Samreen, Naziya , Rhodes, Deborah J. , Johnson, Matthew P. , Hruska, Carrie B.

Mayo Clinic

American Journal of Roentgenology | July 20, 2022 | Volume: 220 | Issue: 1 | Pages: 40-48

10.2214/ajr.21.27047 | PMID 35856455 Get It

Transcatheter edge-to-edge repair in patients with mitral regurgitation and cardiogenic shock: a new therapeutic target
Jung, Richard G. , Santo, Pietro Di , Hibbert, Benjamin , Hibbert, Benjamin , Simard, Trevor

Mayo Clinic

Current Opinion in Critical Care | July 20, 2022 | Volume: 28 | Issue: 4 | Pages: 426-433

10.1097/mcc.0000000000000952 | PMID 35856980 Get It

Purpose of review Cardiogenic shock with significant mitral regurgitation portends a poor prognosis with limited therapeutic options. Herein, we review the available evidence regarding the patient characteristics, management, impact of transcatheter edge-to-edge repair (TEER) on hemodynamics, and clinical outcomes of patients with cardiogenic shock and mitral regurgitation. Recent findings Several observational studies and systematic reviews have demonstrated the feasibility and safety of TEER in cardiogenic shock complicated by degenerative or functional mitral regurgitation. Surgical interventions for mitral regurgitation remain limited owing to the risk profile of patients in cardiogenic shock. TEER has been studied in both degenerative and functional mitral regurgitation and remains feasible in the critically ill population. Moreover, TEER is associated with reduction in mitral regurgitation and improvement in-hospital and long-term mortality. Summary TEER remains a promising therapeutic option in cardiogenic shock complicated by significant mitral regurgitation, but additional research is required to identify patient and procedural characteristics, hemodynamic parameters, and the optimal time for intervention. Moreover, future randomized controlled trials are in progress to evaluate the potential benefit of TEER against medical management in cardiogenic shock and mitral regurgitation.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim, Ellen J. , Mangold, Aaron R. , DeSimone, Jennifer , Seminario‐Vidal, Lucia , Guitart, Joan , Appel, James, Lain, Edward , Korman, Neil J. , Zeitouni, Nathalie C., Nikbakht, Neda , Dawes, Kenneth, Akilov, Oleg E. , Carter, Joi, Kuzel, Timothy M. , Piette, Warren W., Bhatia, Neal , Musiek, Amy , Pariser, David M. , Elston, Dirk M. , Boh, Erin , Pacheco, Theresa , Zwerner, Jeffrey P., Bohjanen, Kimberly , Olsen, Elise A. , Wood, Gary S. , Rumage, Adam, Donini, Oreola , Haulenbeek, Andrea, Schaber, Christopher J. , Straube, Richard , Pullion, Christopher , Rook, Alain H. , Poligone, Brian , Mangold, A R , Akilov, Oleg E , Seminario-Vidal, L , Wong, Henry K. , Geskin, Larisa J. , Shinohara, Michi M. , Kim, Youn H , Duvic, Madeleine , Huen, Auris , Lee, Seung‐Tae , Girardi, Michael , Querfeld, Christiane

Mayo Clinic

JAMA Dermatology | July 20, 2022 | Volume: 158 | Issue: 9 | Pages: 1031

10.1001/jamadermatol.2022.2749 | PMID 35857290 Get It

Importance Given that mycosis fungoides−cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects. Topical synthetic hypericin ointment, 0.25%, activated with visible light is a novel, nonmutagenic photodynamic therapy (PDT). Objectives To determine the efficacy and safety of topical synthetic hypericin ointment, 0.25%, activated with visible light as a nonmutagenic PDT in early-stage MF/CTCL. Design, Settings, and Participants This was a multicenter, placebo-controlled, double-blinded, phase 3 randomized clinical trial (FLASH study) conducted from December 2015 to November 2020 at 39 academic and community-based US medical centers. Participants were adults (≥18 years) with early-stage (IA-IIA) MF/CTCL. Interventions In cycle 1, patients were randomized 2:1 to receive hypericin or placebo to 3 index lesions twice weekly for 6 weeks. In cycle 2, all patients received the active drug for 6 weeks to index lesions. In cycle 3 (optional), both index and additional lesions received active drug for 6 weeks. Main Outcomes and Measures The primary end point was index lesion response rate (ILRR), defined as 50% or greater improvement in modified Composite Assessment of Index Lesion Severity (mCAILS) score from baseline after 6 weeks of therapy for cycle 1. For cycles 2 and 3, open label response rates were secondary end points. Adverse events (AEs) were assessed at each treatment visit, after each cycle, and then monthly for 6 months. Data analyses were performed on December 21, 2020. Results The study population comprised 169 patients (mean [SD] age, 58.4 [16.0] years; 96 [57.8%] men; 120 [72.3%] White individuals) with early-stage MF/CTCL. After 6 weeks of treatment, hypericin PDT was more effective than placebo (cycle 1 ILRR, 16% vs 4%; P = .04). The ILRR increased to 40% in patients who received 2 cycles of hypericin PDT ( P &lt; .001 vs cycle 1 hypericin) and to 49% after 3 cycles ( P &lt; .001 vs cycle 1 hypericin). Significant clinical responses were observed in both patch and plaque type lesions and were similar regardless of age, sex, race, stage IA vs IB, time since diagnosis, and number of prior therapies. The most common treatment-related AEs were mild local skin (13.5%-17.3% across cycles 1-3 vs 10.5% for placebo in cycle 1) and application-site reactions (3.2%-6.9% across cycles 1-3 vs 4% for placebo in cycle 1). No drug-related serious AEs occurred. Conclusion and Relevance The findings of this randomized clinical trial indicate that synthetic hypericin PDT is effective in early-stage patch and plaque MF/CTCL and has a favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT02448381